FDA-2025-P-6223

Requests that the FDA rescind 21 CFR 801.109 in its entirety or substantially narrow the scope of 21 CFR 801.109 by amending it to limit prescription-only status to those devices that present a meaningful potential for harmful misuse or overdose in the absence of practitioner supervision.